Diflunisal Offlabel denied as experimental or investigational by Humana?

Humana's specific coverage criteria for diflunisal offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Diflunisal (Off-Label Use) as Experimental or Investigational

Diflunisal is FDA-approved as an NSAID analgesic, but its use as a transthyretin stabilizer for hereditary transthyretin amyloidosis (hATTR) or transthyretin amyloid cardiomyopathy (ATTR-CM) is off-label. Humana may classify an off-label use as "experimental or investigational" when it concludes the use lacks sufficient evidence to meet its coverage standards. This does not mean the use is fringe or unproven — it reflects how Humana's specific medical-policy process categorizes the evidence at the time of the denial. The classification is challengeable.

## Why This Denial Is Appealable

Diflunisal's use in ATTR amyloidosis has been studied and is referenced in professional society guidelines and expert consensus documents. Several major medical centers with amyloidosis programs use it as part of clinical practice. Humana must apply a coverage determination that is consistent with the level of scientific evidence that exists; if the evidence base has grown since the policy was last updated, the external review process is the mechanism to bring that evidence in front of an independent reviewer who is not bound by the insurer's internal policy date. For off-label use appeals, the key legal hook under many state laws and ERISA is whether the use is supported by peer-reviewed literature or recognized compendia.

## Federal Appeal Framework

Under ACA Section 2719 and ERISA Section 503, experimental/investigational denials are adverse benefit determinations subject to mandatory internal appeal and independent external review. Critically, independent external reviewers apply clinical standards — not just the insurer's policy — which makes external review particularly valuable for off-label use disputes. File the internal appeal within 180 days of the denial. Request external review within four months of the final internal denial. Request expedited review if the clinical situation is urgent.

## Documentation to Gather

• Diagnosis confirmation: Records establishing the ATTR amyloidosis diagnosis, including genetic testing results, cardiac evaluation records, and specialist notes.
• Prescriber medical-necessity letter: A detailed letter from a specialist (ideally a cardiologist or neurologist with amyloidosis experience) explaining the clinical rationale, the evidence base for this use, and why it is appropriate for this patient.
• Literature summary: The prescribing physician or a specialist should compile peer-reviewed publications and relevant professional society guidelines or compendia entries supporting diflunisal for ATTR — without asserting specific trial statistics, just noting the existence and nature of the supporting evidence.
• Prior treatment history: Documentation of other treatments considered or tried and their outcomes.
• Humana's experimental-use policy: Download the current version and the version in effect at denial; map your evidence directly to Humana's stated criteria for what moves a use from investigational to covered.

## Criteria-Mapping Structure

| Humana Experimental/Investigational Criterion | Evidence Rebutting That Classification | |---|---| | [Each criterion verbatim from Humana's policy] | [Peer-reviewed support, guideline reference, or specialist attestation addressing that criterion] |